Objective:

To highlight recently published research by Dana-Farber faculty from May 16 - 31, 2026.

Approach:

Key Findings:

• TAC01-HER2 showed manageable toxicity and early efficacy in HER2-positive tumors.
• Lorlatinib demonstrated unprecedented long-term progression-free survival (PFS) benefits compared to crizotinib.
• Temporary interruption of endocrine therapy for pregnancy in breast cancer patients did not increase the risk of cancer events.

Interpretation:

Limitations:

• The TAC01-HER2 study had a small sample size of 23 patients.
• Long-term follow-up data for overall survival in the CROWN study is still ongoing.
• The POSITIVE trial results require continued follow-up due to the risk of late recurrence.

Conclusion:

Sources:

• Dana-Farber Research News
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.